Redwood City, United States
Avisi Technologies is a burgeoning player in the Health Care and Medical Devices sectors, founded in 2017 and headquartered in the United States. The company is pioneering ophthalmic treatments with its groundbreaking metamaterial technology. Its flagship product, VisiPlate, dubbed as "a nanotech defense against blindness," is a promising implant designed to combat glaucoma, a leading cause of irreversible blindness globally.
Recently, Avisi Technologies secured a $6.33M Seed Round investment on 01 October 2023. Notable investors include Gaingels, Good Growth Capital, and Life Science Angels. Their innovation has not gone unnoticed, as evidenced by accolades like the Ophthalmology Technology Summit People’s Choice Award and being named a finalist at the 2022 FIERCE Life Sciences Innovation Awards.
A member of prestigious incubators like Johnson & Johnson JLABS and UCSF Rosenman Innovators, Avisi Technologies is proving itself as a promising venture worth monitoring in the medical technology landscape.
